Nutr Metab:改善乳腺癌幸存者身心健康和免疫状态组合利器:瑜伽+高剂量维D!

2021-09-13 MedSci原创 MedSci原创

降低体重和身体脂肪百分比,显著降低焦虑水平,改善肩关节活动灵活度,显著提高调节白细胞P53和Bcl2表达!这套疗法真有点东西......

乳腺癌 (BC) 治疗常对患者的心理、身体健康产生不良影响。研究表明,BC幸存者罹患精神疾病,尤其是抑郁、压力和焦虑的风险较高。免疫抑制也是BC治疗的重要副作用之一。

免疫细胞存活受凋亡和抗凋亡基因之间的平衡调节。P53 是一种抗凋亡基因,能调节免疫细胞的功能:然而,BC幸存者白细胞中的p53活性尚未明确。另一方面,NF-éB是免疫、炎症和凋亡等过程的关键调节点。NF-éB能将压力转化为炎症,并降低 Bcl2/Bax 比率。NF-éB 和 p53 之间的平衡影响着细胞活性。

补充疗法,包括营养补充剂和运动训练,是管理乳腺癌的新方法。研究表明,维生素D通过影响p53基因表达发挥作用,抑制NF-éB在人类白细胞中的激活,同时通过调节Bcl2/Bax比率在细胞生存周期中发挥作用。瑜伽疗法则可以减少炎症反应并改善细胞免疫的各种参数,但BC幸存者免疫细胞的分子机制和瑜伽至今的关系尚不清楚。本研究旨在研究瑜伽训练与维生素D补充剂相结合对免疫细胞生存基因表达和乳腺癌幸存者的心理身体状况的影响。

补充VD12周后,患者VD水平显著升高,两组高VD组与Y+LD组差异有统计学意义(F=6.5, p=0.005, ηp2=0.33)。经过12周的瑜伽训练后,Y+HD组和Y+LD组的体脂率明显低于HD组(F=7.2, p<0.003, ηp2=0.36)。在肩关节灵活性方面,两组间有显著差异(同侧:F=7.8, p=0.002, ηp2=0.38;对侧:F=6.4 p=0.005, ηp2=0.33);与Rockport步行试验中等效应组也差异明显(F=12.4, p<0.001, ηp2=0.49)。Te Bonferroni事后试验表明,Y+HD组和Y+LD组的肩关节灵活性和Rockport行走能力均显著高于HD组。

与HD组相比,在Y+HD组和Y+LD组的12周瑜伽训练在降低焦虑方面更有效。HD组的焦虑无显著变化(p>0.05)。

图1a:干预后各组P53均过表达;两组白细胞P53表达差异有统计学意义(F=7.1, p=0.003)。Te Bonferroni事后检验显示,Y+HD组与Y+LD组差异有统计学意义(p=0.002)。

图1b:干预后各组白细胞NF-κB表达均下调,但组间差异无统计学意义(F=1.5)。p = 0.231)。

图1c:12周的瑜伽训练导致干预后所有组的Bcl2表达上调。两组间白细胞Bcl2表达差异有统计学意义(F=7.5, p=0.003)。Te Bonferroni后测显示,Y+HD组与HD组之间有显著差异(p=0.002)

图1d:干预后各组白细胞Bax表达均下降调控,但组间无显著差异(F=2.6,p = 0.091)。

下图为干预后白细胞生存相关基因表达变化与焦虑、VD和皮质醇水平之间的相关性。焦虑水平与NF-éB 和 Bax 表达显著正相关关系,并且与 p53 和 Bcl2 表达负相关。皮质醇水平与NF-éB表达显著正相关,与 p53 和 Bcl2 表达负相关。此外,VD 仅与 p53 和 Bcl2 表示相关。

本研究结果表明,与HD组相比,12周的瑜伽训练可以降低体重和身体脂肪百分比,对身体组成产生积极影响。两组瑜伽组的焦虑水平显著降低,并改善肩关节活动灵活度。瑜伽训练与高剂量的VD补充剂显著提高调节白细胞P53和Bcl2,但未发现NF-éB和Bax显著下调。

综上所述,将瑜伽训练与高剂量VD补充相结合,对BC幸存者的免疫细胞存活相关的关键分子标志物、身体健康和心理状态有进一步的好处。因此,我们将鼓励BC幸存者进行瑜伽训练,同时摄入高剂量的VD补充剂,以求更多健康获益。

原始出处:

Khedmati Zare V, Javadi M, Amani-Shalamzari S, Kaviani M. The high dose of vitamin D supplementation combined with yoga training improve the leukocytes cell survival-related gene expression in breast cancer survivors.Nutr Metab (Lond). 2021 Aug 28;18(1):80

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1888339, encodeId=07a918883391f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Apr 10 17:35:39 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896892, encodeId=4a081896892fd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 01 21:35:39 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942140, encodeId=e3e4194214026, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Sep 22 13:35:39 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037449, encodeId=abe8203e44982, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Wed Aug 24 08:35:39 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283539, encodeId=94e6128353906, content=<a href='/topic/show?id=1c1868e1325' target=_blank style='color:#2F92EE;'>#瑜伽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68713, encryptionId=1c1868e1325, topicName=瑜伽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Sep 14 05:35:39 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016979, encodeId=586210169e9a4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1655577185, createdName=龙心, createdTime=Mon Sep 13 10:24:39 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
    2022-04-10 guojianrong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1888339, encodeId=07a918883391f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Apr 10 17:35:39 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896892, encodeId=4a081896892fd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 01 21:35:39 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942140, encodeId=e3e4194214026, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Sep 22 13:35:39 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037449, encodeId=abe8203e44982, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Wed Aug 24 08:35:39 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283539, encodeId=94e6128353906, content=<a href='/topic/show?id=1c1868e1325' target=_blank style='color:#2F92EE;'>#瑜伽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68713, encryptionId=1c1868e1325, topicName=瑜伽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Sep 14 05:35:39 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016979, encodeId=586210169e9a4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1655577185, createdName=龙心, createdTime=Mon Sep 13 10:24:39 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
    2021-10-01 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1888339, encodeId=07a918883391f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Apr 10 17:35:39 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896892, encodeId=4a081896892fd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 01 21:35:39 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942140, encodeId=e3e4194214026, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Sep 22 13:35:39 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037449, encodeId=abe8203e44982, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Wed Aug 24 08:35:39 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283539, encodeId=94e6128353906, content=<a href='/topic/show?id=1c1868e1325' target=_blank style='color:#2F92EE;'>#瑜伽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68713, encryptionId=1c1868e1325, topicName=瑜伽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Sep 14 05:35:39 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016979, encodeId=586210169e9a4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1655577185, createdName=龙心, createdTime=Mon Sep 13 10:24:39 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
    2021-09-22 amy0550
  4. [GetPortalCommentsPageByObjectIdResponse(id=1888339, encodeId=07a918883391f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Apr 10 17:35:39 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896892, encodeId=4a081896892fd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 01 21:35:39 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942140, encodeId=e3e4194214026, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Sep 22 13:35:39 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037449, encodeId=abe8203e44982, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Wed Aug 24 08:35:39 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283539, encodeId=94e6128353906, content=<a href='/topic/show?id=1c1868e1325' target=_blank style='color:#2F92EE;'>#瑜伽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68713, encryptionId=1c1868e1325, topicName=瑜伽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Sep 14 05:35:39 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016979, encodeId=586210169e9a4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1655577185, createdName=龙心, createdTime=Mon Sep 13 10:24:39 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1888339, encodeId=07a918883391f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Apr 10 17:35:39 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896892, encodeId=4a081896892fd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 01 21:35:39 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942140, encodeId=e3e4194214026, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Sep 22 13:35:39 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037449, encodeId=abe8203e44982, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Wed Aug 24 08:35:39 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283539, encodeId=94e6128353906, content=<a href='/topic/show?id=1c1868e1325' target=_blank style='color:#2F92EE;'>#瑜伽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68713, encryptionId=1c1868e1325, topicName=瑜伽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Sep 14 05:35:39 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016979, encodeId=586210169e9a4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1655577185, createdName=龙心, createdTime=Mon Sep 13 10:24:39 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
    2021-09-14 wjywjy
  6. [GetPortalCommentsPageByObjectIdResponse(id=1888339, encodeId=07a918883391f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sun Apr 10 17:35:39 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896892, encodeId=4a081896892fd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 01 21:35:39 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942140, encodeId=e3e4194214026, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Sep 22 13:35:39 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037449, encodeId=abe8203e44982, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Wed Aug 24 08:35:39 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283539, encodeId=94e6128353906, content=<a href='/topic/show?id=1c1868e1325' target=_blank style='color:#2F92EE;'>#瑜伽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68713, encryptionId=1c1868e1325, topicName=瑜伽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Sep 14 05:35:39 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016979, encodeId=586210169e9a4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1655577185, createdName=龙心, createdTime=Mon Sep 13 10:24:39 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
    2021-09-13 龙心

    学习

    0

相关资讯

PLoS One:治疗化生性乳腺癌,选保乳手术+放疗还是乳房切除术效果更好?

化生性乳腺癌 (MBC)的治疗中,保留乳房手术加放疗和乳房切除术的不同结果:一项基于人群的研究。

IJC:超60万女性数据,揭示成人体重变化与绝经前乳腺癌风险的关系

本项结果可能有助于理解乳腺癌的病因,并有助于风险分层。我们有必要了解这一发现背后的机制,这可能为乳腺癌的预防提供方向。

Clin Cancer Res:根据患者来源移植瘤的植入情况预测患者的肿瘤复发风险?

耐药性肿瘤患者来源的移植瘤的植入成功与否,或可预测患者的肿瘤复发风险

J Oncol:首次报道!LOC105371267变异对中国北方汉族女性乳腺癌易感性的影响

本研究首次揭示了LOC105371267对中国北方汉族女性BC易感性的影响, LOC105371267变异可能是 BC 风险的遗传标记, 或能用于BC 的诊断和预测。

Clin Cancer Res:口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的疗效和安全性

口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的安全性良好,而且表现出初步的抗肿瘤活性

JAMA Surg:年轻乳腺癌患者接受乳房切除手术对其生活质量的影响

年轻乳腺癌患者接受乳房切除后可导致BREAST-Q量表评分显著下降,即使接受乳房重建其生活质量也会受到显著影响